CTLA4 and melanoma: Moreover, Veatch and colleagues recently identified HLA-DQB1*03-restricted BRAFV600E-specific CD4+ T cells in an acral melanoma patient, who nonetheless developed metastases under ipilimumab (anti-CTLA-4) immunotherapy (97).